Zolbetuximab
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer
Trial Timeline
Jun 8, 2018 → Jun 9, 2020
NCT ID
NCT03528629About Zolbetuximab
Zolbetuximab is a pre-clinical stage product being developed by Astellas Pharma for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03528629. Target conditions include Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06048081 | Pre-clinical | Active |
| NCT06902545 | Pre-clinical | Recruiting |
| NCT04086758 | Phase 1 | Completed |
| NCT03528629 | Pre-clinical | Completed |
Competing Products
20 competing products in Gastric Cancer